Remote STATE Training for Insomnia in Older Adults (rSTATE)
Remote STATE Training for Insomnia in Older Adults - Phase II
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Kathy Wannaviroj
- Phone Number: (415) 568-3565
- Email: rstate@brainhq.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94111
- Posit Science Corporation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who are 65 years of age or older. The inclusion age of ≥ 65 is in accordance with the FDA's Guideline for Industry Studies in Support of Special Populations (Geriatrics ICH-E7), which uses 65 as its cutoff for defining the geriatric population prone to insomnia.
- Participants who have an Insomnia disorder diagnosis per DSM-V.
- Participants who exhibit > 30 minutes sleep onset latency (SOL); and/or > 30 minutes wake after sleep onset (WASO).
- Participants must be a US resident.
- Participants who are fluent English speakers, per self-report, to ensure reasonable neuropsychological results on key assessments.
- Participants must have adequate sensorimotor capacity to perform the program, including visual capacity adequate to read from a computer screen at a normal viewing distance, auditory capacity adequate to understand normal speech, and motor capacity adequate to control a computer mouse or a tablet.
Exclusion Criteria:
- Participants who score ≥ 4 on the Cognitive Function Index (CFI).
- Participants who self-report vision or hearing difficulties that would interfere with the ability to complete the study tasks.
- Participants with past or present psychosis, schizophrenia, or bipolar disorder. Participants with other untreated psychiatric disorder, including substance abuse/dependence disorders.
- Participants with a seizure disorder.
- Participants with untreated obstructive sleep apnea, diagnosis of other sleep disorders not attributable to a primary sleep regulation problem (e.g., restless legs syndrome).
- Participants with a recent hospitalization, ongoing chemotherapy or other cancer treatment.
- Participants enrolled in a concurrent clinical trial involving an investigational pharmaceutical, nutraceutical, medical device, or behavioral treatment (CBTi) in the last 12-months that could affect the outcome of this study, or concurrent engagement in another insomnia treatment, per self-report. However, participation in standard treatments not known to affect sleep (e.g., occupational therapy) or use of prescribed medications (e.g., anti-depressants) is allowable if stable on medications for > 3 months.
- Participants who are using computer-based cognitive training programs or have used it within a month of the consent date.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental Treatment
Computerized plasticity-based adaptive cognitive training requiring a total maximum of 36 treatment sessions, up to 5 sessions per week, ~36 minutes per session.
|
Training on computerized exercises that targets processing speed, attention and executive function for about 36 minutes per session, 5 sessions per week for a total of 36 sessions.
|
|
Active Comparator: Active Comparator
Sleep hygiene education
|
Access to sleep hygiene education materials
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Sleep Efficiency
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Sleep Time
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Wake After Sleep Onset
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Sleep Onset Latency
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Total Time in Bed
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Total Wake Time
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Sleep Quality
Time Frame: At 9 weeks and at 6 months
|
Evaluated using the Insomnia Severity Index (ISI).
|
At 9 weeks and at 6 months
|
|
Patient Health Questionnaire - 8 questions (PHQ-8) Score
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Generalized Anxiety Disorder Questionnaire - 7 questions (GAD-7) Score
Time Frame: At 9 weeks and at 6 months
|
At 9 weeks and at 6 months
|
|
|
Percentage of Time Spent in Stage N1 Sleep
Time Frame: At 9 weeks
|
At 9 weeks
|
|
|
Percentage of Time Spent in Stage N2 Sleep
Time Frame: At 9 weeks
|
At 9 weeks
|
|
|
Percentage of Time Spent in Stage N3 Sleep
Time Frame: At 9 weeks
|
At 9 weeks
|
|
|
Percentage of Time Spent in REM Sleep
Time Frame: At 9 weeks
|
At 9 weeks
|
|
|
REM Latency
Time Frame: At 9 weeks
|
At 9 weeks
|
|
|
Gradual-Onset Continuous Performance Task Score
Time Frame: At 9 weeks and at 6 months
|
To measure task engagement
|
At 9 weeks and at 6 months
|
|
Complex Set-Shifting Score
Time Frame: At 9 weeks and at 6 months
|
To measure task engagement
|
At 9 weeks and at 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Andrew Krystal, MD, University of California, San Francisco
- Principal Investigator: Thomas Van Vleet, PhD, Posit Science Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PSC-0702-22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.